WO2007092414A3 - Use of phosphatases to treat tumors overexpressing n-cor - Google Patents

Use of phosphatases to treat tumors overexpressing n-cor Download PDF

Info

Publication number
WO2007092414A3
WO2007092414A3 PCT/US2007/003095 US2007003095W WO2007092414A3 WO 2007092414 A3 WO2007092414 A3 WO 2007092414A3 US 2007003095 W US2007003095 W US 2007003095W WO 2007092414 A3 WO2007092414 A3 WO 2007092414A3
Authority
WO
WIPO (PCT)
Prior art keywords
cor
provides
patient
suffering
tumor overexpressing
Prior art date
Application number
PCT/US2007/003095
Other languages
French (fr)
Other versions
WO2007092414A8 (en
WO2007092414A2 (en
Inventor
Zhengping Zhuang
Edward H Oldfield
Deric M Park
Irina Lubensky
Jie Li
John S Kovach
Original Assignee
Lixte Biotechnology Holdings I
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Holdings I, Us Gov Health & Human Serv filed Critical Lixte Biotechnology Holdings I
Priority to EP07763614A priority Critical patent/EP1986619A4/en
Priority to CA002641308A priority patent/CA2641308A1/en
Publication of WO2007092414A2 publication Critical patent/WO2007092414A2/en
Publication of WO2007092414A3 publication Critical patent/WO2007092414A3/en
Publication of WO2007092414A8 publication Critical patent/WO2007092414A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

This invention provides a method of treating a patient suffering from a tumor overexpressing N-CoR comprising administering to the patient a phosphatase ligand, alone or in combination with 'a retinoid receptor ligand, a histone deacetylase ligand, or both, in amounts effective to treat the patient. This invention also provides a method of inhibiting tumor growth in a patient suffering from a tumor overexpressing N-CoR. This invention further provides a method of identifying a compound or a mixture of compounds capable of inducing differentiation of cells of a tumor overexpressing N- CoR. This invention still further provides a method of determining the likelihood of successfully treating a subject suffering from a tumor overexpressing N-CoR. This invention also provides a method of assessing the- likelihood that a patient is suffering from a tumor overexpressing N-CoR. This invention yet also provides a method of assessing the likelihood that a patient previously suffering from and treated for a tumor overexpressing N-CoR has suffered a recurrence of a tumor overexpressing N-CoR. Finally, this invention provides analogous methods for use on glioblastoma multiforme.
PCT/US2007/003095 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor WO2007092414A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07763614A EP1986619A4 (en) 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor
CA002641308A CA2641308A1 (en) 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77116306P 2006-02-06 2006-02-06
US60/771,163 2006-02-06
US79720106P 2006-05-02 2006-05-02
US60/797,201 2006-05-02

Publications (3)

Publication Number Publication Date
WO2007092414A2 WO2007092414A2 (en) 2007-08-16
WO2007092414A3 true WO2007092414A3 (en) 2008-05-15
WO2007092414A8 WO2007092414A8 (en) 2008-09-04

Family

ID=38345726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003095 WO2007092414A2 (en) 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor

Country Status (3)

Country Link
EP (1) EP1986619A4 (en)
CA (1) CA2641308A1 (en)
WO (1) WO2007092414A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101662939B (en) 2007-02-06 2015-11-25 利克斯特生物技术公司 Oxa-bicyclo heptane and oxabicyclo heptene, their preparation and purposes
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
MX2010003417A (en) 2007-10-01 2010-09-10 Lixte Biotechnology Inc Hdac inhibitors.
WO2010147612A1 (en) * 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
EP2309853A4 (en) * 2008-08-01 2012-04-25 Lixte Biotechnology Inc Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
CA2827015A1 (en) * 2010-02-11 2011-08-18 The Royal Institution For The Advancement Of Learning/Mcgill University Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties
AU2013282365A1 (en) 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
KR20160004299A (en) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 Formulations of oxabicycloheptanes and oxabicycloheptenes
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
WO2016134257A1 (en) 2015-02-19 2016-08-25 Lixter Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
CN113150030A (en) 2015-05-15 2021-07-23 莱克斯特生物技术公司 Oxabicycloheptane prodrugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209934A1 (en) * 2001-03-23 2004-10-21 Mccluskey Adam Protein phosphate inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
DE10038043B4 (en) * 2000-08-02 2006-09-07 Walter, Michael, Dr. Phamacologically active substance for the treatment of cardiovascular diseases
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
FR2872704B1 (en) * 2004-07-12 2007-11-02 Laurent Schwartz PLURITHERAPY AGAINST CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209934A1 (en) * 2001-03-23 2004-10-21 Mccluskey Adam Protein phosphate inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLASKVICH ET AL.: "Recent discovery and development of protein tyrosine phosphatase inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 12, no. 6, 2002, pages 871 - 905, XP002469921 *
FLICKER ET AL.: "Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-a in SK-BR-3 breast cancer cells", CANCER LETT., vol. 115, 1997, pages 63 - 72, XP008131524 *
KUREBAYASHI ET AL.: "Expression levels of estrogen receptor-a, estrogen receptor-b, coactivators, and corepressors in breast cancer", CLIN. CANCER RES., vol. 6, February 2000 (2000-02-01), pages 512 - 518, XP002289439 *
LAVINSKY ET AL.: "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes", PROC. NATL. ACAD. SCI., vol. 95, March 1998 (1998-03-01), pages 2920 - 2925, XP008131523 *
See also references of EP1986619A4 *

Also Published As

Publication number Publication date
EP1986619A4 (en) 2010-04-28
EP1986619A2 (en) 2008-11-05
WO2007092414A8 (en) 2008-09-04
WO2007092414A2 (en) 2007-08-16
CA2641308A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
WO2007092414A8 (en) Use of phosphatases to treat tumors overexpressing n-cor
WO2009036188A3 (en) Insulin-like growth factor binding protein 7 for treatment of cancer
Catalano et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo
Iamartino et al. Calcium-sensing receptor in colorectal inflammation and cancer: Current insights and future perspectives
WO2007117344A3 (en) Differentiating and/or identifying tissue regions innervated by targeted nerves
Zhang et al. Metformin ameliorates BSCB disruption by inhibiting neutrophil infiltration and MMP‐9 expression but not direct TJ proteins expression regulation
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
WO2007133250A3 (en) Compositions and methods for diagnosing and treating cancer
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
WO2007103114A3 (en) Notch inhibition in the treatment or prevention of atherosclerosis
WO2007064882A3 (en) Treatment of conditions involving demyelination
WO2007112316A3 (en) Mycobacterial immunotherapy for cancer treatment
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2009036149A3 (en) Methods for treatment of degenerative disease associated with apoptosis
WO2009073575A3 (en) Methods for treating induced cellular proliferative disorders
WO2006071456A3 (en) Inhibition of hsp27 phosphorylation for treatment of blistering disorders
Nagai et al. Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
Neirinckx et al. Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy
WO2006113579A3 (en) Tumor inhibition by modulating sprouty expression or activity
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2004092735A3 (en) Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2019512021A5 (en)
Currie et al. Using animal models to understand cancer pain in humans
WO2008147869A3 (en) Markers and methods for assessing and treating crohn's disease and related disorders
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2641308

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007763614

Country of ref document: EP